Business Wire

TRUSTECH (incorporating CARTES), The Global Event Dedicated to Trust-Based Technologies: 2016 Event Will Be The Best Yet


New name, new format, new targets, new venue… there’s no doubt this year’s global event dedicated to secure payment, identification and connections is going to break the mould.

This Smart News Release features multimedia. View the full release here:

JB Straubel - Co-founder & CTO, Tesla Motors (Photo: Business Wire)

JB Straubel - Co-founder & CTO, Tesla Motors (Photo: Business Wire)

The show was first held over thirty years ago under the name “Cartes Secure Connexions”, to promote the new-born technology of smartcards. Now it has been re-named “TRUSTECH (incorporating CARTES)”, a better reflection of the way the industry and the event have evolved, and of its focus on trust-based technologies.

What’s more, this event – redesigned to encourage networking and to provide an outstanding programme of addresses – will now be taking place at a new venue which offers two events in one: the CARTES Exhibition and the TRUSTECH Confex will be held in Cannes at the Palais des Festivals from 29 November to 1 December 2016.

TRUSTECH (incorporating CARTES) is expected to bring together more than 18,000 participants from 130 countries, 400 exhibitors and sponsors, and 250 speakers.


By offering two events in one, TRUSTECH – Pay, Identify, Connect & Secure represents a unique opportunity to meet the whole industry and get an insight into the latest innovations in payments and identification ecosystem.

  • CARTES, a TRUSTECH EVENT: The Smart Card Ecosystem and the latest trends

Created in 1985, CARTES is the leading global trade show for Smart Card Manufacturing, Materials and Hardware for Payments and ID security.

Three days of catching up, developing sales and strengthening your business:

  • Manufacturing & personalization equipment
  • Test equipment, system certification & maintenance
  • Integrated circuits (dies with or without a specific package)
  • Electronic components & sensors
  • Materials, consumables & accessories
  • Cards; micromodules for cards and other form factors (IoT)
  • Terminals, readers and other infrastructure devices and equipment
  • IC solutions (tools, services, process)
  • Generic OS for cards, readers and terminals
  • Services for manufacturing and personalization of cards and other form factors

TRUSTECH Confex: The Next Generation of Trust-Based Technologies

The TRUSTECH Confex assembles the next generation of Payments and Identification Ecosystem. Thought leaders from Payments, Financial Services, Commerce, Telco, Identification, Tech and Data Security Ecosystem will share their insights.

Osama Bedier, Founder & CEO of Poynt, and one of the leading figures of the payments industry (formerly VP of Paypal and VP for Payments at Google) will make a keynote.

JB Straubel, Co-founder and CTO of Tesla Motors will give an address on the Internet of Things.

Over 250 international speakers will share their thoughts on top trending topics including:

  • Blockchain
  • Fintech
  • E-ID & E-Governments
  • Data Management

3 days in which to inform, learn and discover

Software and services for:

  • Mobile Telecoms
  • Banking, Payment, Commerce and Loyalty
  • ID, Health, Access Control and Privacy
  • IT Security, Authentication and Trust
  • IoT & M2M

System integration and database management


Cannes and its famous Palais des Festivals has been hand-picked as the new venue for the event. For the duration of the event TRUSTECH will be taking over a town that attracts over 300,000 attendees per year, making it the number 2 location for Business Tourism in all of France. What’s more, the venue is tailor-made for entertaining, networking and after-hours relaxation.

«The decision to locate the event in Cannes enables us to welcome the TRUSTECH and CARTES Community in a unique and welcoming location, to strengthen the international dimension of the event and to facilitate the networking. The Palais des Festivals venue fully meets our needs and we are pleased about the welcome that has been reserved to us » shared Claire de Longeaux, TRUSTECH (incorporating CARTES) Director.

To find out more and to register, go to


The COMEXPOSIUM Group, one of the world leaders in event organization, is involved in more than 170 BtoC and BtoB events, covering 11 different sectors of activity such as food, agriculture, fashion, homeland security, construction, high-tech, optics and transport. COMEXPOSIUM hosts 45.000 exhibitors and more than 3 million visitors in 26 countries around the world.

Contact information

Media contact:
Agency Vianova
Sandra Codognotto, +33 01 53 32 28 58

Om Business Wire

Business Wire
Business Wire
24 Martin Lane
EC4R 0DR London

+44 20 7626 1982

(c) 2018 Business Wire, Inc., All rights reserved.

Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.

Følg saker fra Business Wire

Registrer deg med din epostadresse under for å få de nyeste sakene fra Business Wire på epost fortløpende. Du kan melde deg av når som helst.

Siste saker fra Business Wire

Clovis Oncology Initiates Early Access Program for Rucaparib as Treatment and as Maintenance Therapy in Recurrent Ovarian Cancer in Europe23.3.2018 12:52Pressemelding

Clovis Oncology, Inc. (NASDAQ:CLVS) today announced the initiation of an early access program in Europe for rucaparib for treatment and as maintenance therapy in recurrent ovarian cancer. The program will be overseen and implemented by Caligor Coghlan, which specializes in early access to medicines. The program, to be known as the Rucaparib Access Program (RAP), will enable participation from certain countries in Europe, where permitted by applicable rules, procedures and regulatory authorities. The RAP protocol allows for rucaparib treatment of an individual patient with third-line or greater BRCA mutant epithelial, fallopian tube, or primary peritoneal ovarian cancer who has platinum-sensitive disease and is unable to tolerate further platinum-based chemotherapy or has platinum-resistant disease and needs treatment with single agent rucaparib. The RAP protocol will also provide access to rucaparib for maintenance therapy of an individual patient with recurrent epithelial ovarian, fal

CHMP Grants Positive Opinion for Clovis Oncology’s Rubraca® (rucaparib) Tablets23.3.2018 12:50Pressemelding

Clovis Oncology, Inc. (NASDAQ: CLVS) today announced that the European Union’s (EU) European Medicines Agency (EMA) Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion recommending the granting of a conditional marketing authorization for Rubraca as monotherapy treatment of adult patients with platinum sensitive, relapsed or progressive, BRCA mutated (germline and/or somatic), high-grade epithelial ovarian, fallopian tube, or primary peritoneal cancer, who have been treated with two or more prior lines of platinum based chemotherapy, and who are unable to tolerate further platinum based chemotherapy. The European Marketing Authorization application for the treatment indication was based on objective response rate and duration of response results from two multicenter, single-arm, open-label clinical trials, Study 10 and ARIEL2, in women with advanced BRCA mutant ovarian cancer who had progressed after two or more prior chemotherapies. “The recommendation

Janssen Announces Positive CHMP Opinion for JULUCATM▼ (dolutegravir/rilpivirine)23.3.2018 12:46Pressemelding

The Janssen Pharmaceutical Companies of Johnson & Johnson today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a Positive Opinion recommending marketing authorisation for JULUCA™ (dolutegravir 50mg [ViiV Healthcare UK Ltd]/rilpivirine 25mg [Janssen Sciences Ireland UC]). Dolutegravir/rilpivirine is a single-pill, two-drug regimen for the treatment of human immunodeficiency virus type 1 (HIV-1) infection in adults who are virologically suppressed (HIV-1 RNA <50 c/mL) on a stable antiretroviral regimen for at least six months with no history of virological failure and no known or suspected resistance to any non-nucleoside reverse transcriptase inhibitor (NNRTI) or integrase strand transfer inhibitor (INSTI).1 “We are delighted to be one step closer to bringing JULUCA™ to people living with HIV in Europe,” said Mathai Mammen, M.D., Ph.D., Global Head, Janssen Research & Development, LLC. “Building on our 25-year c

Aitheon Executives Educate World Leaders on Benefits, Challenges of AI at the Annual World Government Summit in Dubai23.3.2018 12:00Pressemelding

Aitheon, makers of the world’s first blockchain-powered platform to solve real problems by integrating AI, robotics, IoT, human specialists and cryptocurrency, announced today that executives from the company held a series of high-level briefings with world leaders at the Annual World Government Summit in Dubai. Briefings covered the benefits and challenges of AI, and revolutionary new solutions to world challenges made possible by transformative new technologies. (Read the full release at This press release features multimedia. View the full release here: Aitheon founder and CEO, Andrew Archer, and Chief Strategy Officer, Ryan Burleson, were invited to brief leaders at the Summit by Cyrus Hodes, Co-founder and Director of the AI Initiative, an undertaking of the Future Society at Harvard University’s Kennedy School. Archer and Burleson addressed a variety of AI-related topics, including the impact of AI on

ViiV Healthcare Gains CHMP Positive Opinion for Juluca (dolutegravir/rilpivirine) in Europe23.3.2018 11:27Pressemelding

ViiV Healthcare, the global specialist HIV company, majority owned by GlaxoSmithKline, with Pfizer Inc. and Shionogi Limited as shareholders, today announced that the European Committee for Medicinal Products for Human Use (CHMP) has issued a Positive Opinion recommending marketing authorisation for Juluca (dolutegravir/rilpivirine) for the treatment of HIV infection in adults who are virologically suppressed (HIV-1 RNA less than 50 copies per mL) on a stable antiretroviral regimen for at least six months with no history of virological failure and no known or suspected resistance to any non-nucleoside reverse transcriptase inhibitor or integrase inhibitor. The 2-drug regimen comprises dolutegravir 50mg (ViiV Healthcare) and rilpivirine 25mg (Janssen Sciences Ireland UC). Deborah Waterhouse, Chief Executive Officer at ViiV Healthcare commented: “Today is an important milestone for people living with HIV in Europe. It takes us a step closer to offering the first, single-pill, 2-drug regi

Smiths Detection Hold Baggage Scanner Meets Highest Security Standards in EU23.3.2018 07:00Pressemelding

The Smiths Detection HI-SCAN 10080 XCT has achieved ECAC approval as a Standard 3.1 explosives detection system for hold baggage – the highest, defined security standard in the EU. This significant advance was made possible by using a dual-view, dual-energy line scanner with high resolution 3D Computed Tomography (CT) to deliver exceptional data. This press release features multimedia. View the full release here: Smiths Detection HI-SCAN 10080 XCT (Graphic: Business Wire) This achievement gives airports currently upgrading to Standard 3 technology, the option to increase detection levels even further to 3.1; and any standard 3 systems already installed can be easily elevated to 3.1 via a software upgrade. The detection algorithms are interchangeable on a bag by bag basis depending on the destination and associated risk level. This offers additional flexibility and productivity. “With the capability to meet detection requirements